Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial - Platzbecker, Uwe; Krämer, Alwin; Bochtler, Tilmann (The lancet. Oncology, 2018)
Gesehen am 23.04.2020